Research ExplorerPublicationsElotuzumab, lenalidomide, and dexamethasone in RRMM: final o...

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Standard

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. / Dimopoulos, Meletios A; Lonial, Sagar; White, Darrell; Moreau, Philippe; Weisel, Katja; San-Miguel, Jesus; Shpilberg, Ofer; Grosicki, Sebastian; Špička, Ivan; Walter-Croneck, Adam; Magen, Hila; Mateos, Maria-Victoria; Belch, Andrew; Reece, Donna; Beksac, Meral; Spencer, Andrew; Oakervee, Heather; Orlowski, Robert Z; Taniwaki, Masafumi; Röllig, Christoph; Einsele, Hermann; Matsumoto, Morio; Wu, Ka Lung; Anderson, Kenneth C; Jou, Ying-Ming; Ganetsky, Alex; Singhal, Anil K; Richardson, Paul G.

In: BLOOD CANCER J, Vol. 10, No. 9, 04.09.2020, p. 91.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dimopoulos, MA, Lonial, S, White, D, Moreau, P, Weisel, K, San-Miguel, J, Shpilberg, O, Grosicki, S, Špička, I, Walter-Croneck, A, Magen, H, Mateos, M-V, Belch, A, Reece, D, Beksac, M, Spencer, A, Oakervee, H, Orlowski, RZ, Taniwaki, M, Röllig, C, Einsele, H, Matsumoto, M, Wu, KL, Anderson, KC, Jou, Y-M, Ganetsky, A, Singhal, AK & Richardson, PG 2020, 'Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study', BLOOD CANCER J, vol. 10, no. 9, pp. 91. https://doi.org/10.1038/s41408-020-00357-4

APA

Dimopoulos, M. A., Lonial, S., White, D., Moreau, P., Weisel, K., San-Miguel, J., Shpilberg, O., Grosicki, S., Špička, I., Walter-Croneck, A., Magen, H., Mateos, M-V., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., ... Richardson, P. G. (2020). Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. BLOOD CANCER J, 10(9), 91. https://doi.org/10.1038/s41408-020-00357-4

Vancouver

Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. BLOOD CANCER J. 2020 Sep 4;10(9):91. https://doi.org/10.1038/s41408-020-00357-4

Bibtex

@article{688797130cd641398a69f9381b0aab01,
title = "Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study",
abstract = "Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ERd) significantly improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd) in patients with RRMM and 1-3 prior lines of therapy (LoTs). We report results from the pre-planned final OS analysis after a minimum follow-up of 70.6 months, the longest reported for an antibody-based triplet in RRMM. Overall, 646 patients with RRMM and 1-3 prior LoTs were randomized 1:1 to ERd or Rd. PFS and overall response rate were co-primary endpoints. OS was a key secondary endpoint, with the final analysis planned after 427 deaths. ERd demonstrated a statistically significant 8.7-month improvement in OS versus Rd (median, 48.3 vs 39.6 months; hazard ratio, 0.82 [95.4% Cl, 0.68-1.00]; P = 0.0408 [less than allotted α of 0.046]), which was consistently observed across key predefined subgroups. No additional safety signals with ERd at extended follow-up were reported. ERd is the first antibody-based triplet regimen shown to significantly prolong OS in patients with RRMM and 1-3 prior LoTs. The magnitude of OS benefit was greatest among patients with adverse prognostic factors, including older age, ISS stage III, IMWG high-risk disease, and 2-3 prior LoTs.",
author = "Dimopoulos, {Meletios A} and Sagar Lonial and Darrell White and Philippe Moreau and Katja Weisel and Jesus San-Miguel and Ofer Shpilberg and Sebastian Grosicki and Ivan {\v S}pi{\v c}ka and Adam Walter-Croneck and Hila Magen and Maria-Victoria Mateos and Andrew Belch and Donna Reece and Meral Beksac and Andrew Spencer and Heather Oakervee and Orlowski, {Robert Z} and Masafumi Taniwaki and Christoph R{\"o}llig and Hermann Einsele and Morio Matsumoto and Wu, {Ka Lung} and Anderson, {Kenneth C} and Ying-Ming Jou and Alex Ganetsky and Singhal, {Anil K} and Richardson, {Paul G}",
year = "2020",
month = sep,
day = "4",
doi = "10.1038/s41408-020-00357-4",
language = "English",
volume = "10",
pages = "91",
journal = "BLOOD CANCER J",
issn = "2044-5385",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

AU - Dimopoulos, Meletios A

AU - Lonial, Sagar

AU - White, Darrell

AU - Moreau, Philippe

AU - Weisel, Katja

AU - San-Miguel, Jesus

AU - Shpilberg, Ofer

AU - Grosicki, Sebastian

AU - Špička, Ivan

AU - Walter-Croneck, Adam

AU - Magen, Hila

AU - Mateos, Maria-Victoria

AU - Belch, Andrew

AU - Reece, Donna

AU - Beksac, Meral

AU - Spencer, Andrew

AU - Oakervee, Heather

AU - Orlowski, Robert Z

AU - Taniwaki, Masafumi

AU - Röllig, Christoph

AU - Einsele, Hermann

AU - Matsumoto, Morio

AU - Wu, Ka Lung

AU - Anderson, Kenneth C

AU - Jou, Ying-Ming

AU - Ganetsky, Alex

AU - Singhal, Anil K

AU - Richardson, Paul G

PY - 2020/9/4

Y1 - 2020/9/4

N2 - Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ERd) significantly improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd) in patients with RRMM and 1-3 prior lines of therapy (LoTs). We report results from the pre-planned final OS analysis after a minimum follow-up of 70.6 months, the longest reported for an antibody-based triplet in RRMM. Overall, 646 patients with RRMM and 1-3 prior LoTs were randomized 1:1 to ERd or Rd. PFS and overall response rate were co-primary endpoints. OS was a key secondary endpoint, with the final analysis planned after 427 deaths. ERd demonstrated a statistically significant 8.7-month improvement in OS versus Rd (median, 48.3 vs 39.6 months; hazard ratio, 0.82 [95.4% Cl, 0.68-1.00]; P = 0.0408 [less than allotted α of 0.046]), which was consistently observed across key predefined subgroups. No additional safety signals with ERd at extended follow-up were reported. ERd is the first antibody-based triplet regimen shown to significantly prolong OS in patients with RRMM and 1-3 prior LoTs. The magnitude of OS benefit was greatest among patients with adverse prognostic factors, including older age, ISS stage III, IMWG high-risk disease, and 2-3 prior LoTs.

AB - Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ERd) significantly improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd) in patients with RRMM and 1-3 prior lines of therapy (LoTs). We report results from the pre-planned final OS analysis after a minimum follow-up of 70.6 months, the longest reported for an antibody-based triplet in RRMM. Overall, 646 patients with RRMM and 1-3 prior LoTs were randomized 1:1 to ERd or Rd. PFS and overall response rate were co-primary endpoints. OS was a key secondary endpoint, with the final analysis planned after 427 deaths. ERd demonstrated a statistically significant 8.7-month improvement in OS versus Rd (median, 48.3 vs 39.6 months; hazard ratio, 0.82 [95.4% Cl, 0.68-1.00]; P = 0.0408 [less than allotted α of 0.046]), which was consistently observed across key predefined subgroups. No additional safety signals with ERd at extended follow-up were reported. ERd is the first antibody-based triplet regimen shown to significantly prolong OS in patients with RRMM and 1-3 prior LoTs. The magnitude of OS benefit was greatest among patients with adverse prognostic factors, including older age, ISS stage III, IMWG high-risk disease, and 2-3 prior LoTs.

U2 - 10.1038/s41408-020-00357-4

DO - 10.1038/s41408-020-00357-4

M3 - SCORING: Journal article

C2 - 32887873

VL - 10

SP - 91

JO - BLOOD CANCER J

JF - BLOOD CANCER J

SN - 2044-5385

IS - 9

ER -